Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either.

NVIDIA, Albemarle and Axsome Therapeutics emerge as standout plays as AI, clean energy and healthcare draw massive capital in a split 2026 market.

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and sixteen have given a buy recommendation to the company. The average 12 month

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Alkem a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The healthcare company is set to release its fourth-quarter results later this month.

Axsome Therapeutics' current product lineup has been driving solid revenue growth. The biotech should earn several approvals or label expansions in the next few years.

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 30.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,902 shares of the company's stock after acquiring an additional 15,934 shares during the quarter. Universal Beteiligungs